Original Paper
Neuroepidem iology 2002;21:202–206
Service-Based Survey of D yst onia in
M unich
E. Castelon Konkiew itza I. Trender-Gerhard a C. Kam m b T. Warner c
Y. Ben-Shlom o c T. Gasser b B. Conrad a A.O. Ceballos-Baum ann a
Departm ents of a Neurology, Klinikum rechts der Isar, Technische Universität M ünchen, and b Neurology,
Klinikum Grosshadern, Ludw ig-M axim ilians Universität M ünchen, M unich, Germ any, and
c The Epidem iological Study of Dystonia in Europe (ESDE) Collaborative Group
Abstract
We perform ed a service-based epidem iological study of
dystonia in M unich, Germ any. Due to favourable referral
and treatm ent patterns in the M unich area, w e could provide confident data from dystonia patients seeking botulinum toxin treatm ent. A total of 230 patients w ere ascertained, of w hom 188 had prim ary dystonia. Point prevalence ratios w ere estim ated to be 10.1 (95% confidence
interval 8.4–11.9) per 100,000 for focal and 0.3 (0.0–0.6)
for generalised prim ary dystonia. The m ost com m on
focal prim ary dystonias w ere cervical dystonia w ith 5.4
(4.2–6.7) and essential blepharospasm w ith 3.1 (2.1–4.1)
per 100,000 follow ed by laryngeal dystonia (spasm odic
dysphonia) w ith 1.0 (0.4–1.5) per 100,000.
Copyright © 2002 S. Karger AG, Basel
Int roduct ion
Dystonia is defined as a syndrome of sustained involuntary muscle contractions, frequently causing twisting,
repetitive movements or abnormal postures [1]. It can
affect virtually any part of the body and is classified
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 2002 S. Karger AG, Basel
0251–5350/02/0214–0202$18.50/0
Accessible online at:
www.karger.com/journals/ned
accordingly. It is also classified by etiology as follows: primary dystonia, where the phenotype is of dystonia alone
with the exception that tremor can be present as well; dystonia-plus syndromes, where the clinical phenotypes include other neurologic features in addition to dystonia (at
present there are two such dystonia-plus conditions:
dopa-responsive dystonia and dystonia-myoclonus); secondary dystonia, resulting from environmental factors
(e.g. drugs, stroke, cerebral palsy, tumors), and finally heredodegenerative diseases, which present as a dystoniaplus syndrome with underlying neurodegeneration (e.g.
Wilson’s disease, Huntington’s disease, X-linked dystonia
parkinsonism) [1].
Historically, dystonia has been considered to be a rare
disorder. The advent of an effective treatment by weakening dystonic muscles with localised injections of botulinum toxin increased clinical interest in the disease and
hence recognition. Due to the high costs associated with
this therapy, dystonia has become a disease with economic implications in terms of public health [2]. Therefore,
epidemiological data can provide important information
for cost analysis as well as for the planning of appropriate
patient care. However, few epidemiologic studies have
been carried out [3–8] (table 1), none so far in Germany.
We present service-based data on the point prevalence of
dystonia in Munich, Germany, that were collected during
a European epidemiological study of dystonia [7, 8].
PD Dr. Andres O. Ceballos-Baumann
Department of Neurology, Klinikum rechts der Isar
TU München, Möhlstrasse 28
D–81675 Munich (Germany)
Tel. +49 89 41404672, Fax +49 89 41404867, E-Mail a.ceballos@lrz.tu-muenchen.de
Downloaded by:
UB der LMU München
129.187.254.47 - 8/12/2013 12:03:49 PM
Key Words
Dystonia W Prevalence W Botulinum toxin W Epidem iology W
Munich
Table 1 . Prevalence ratios per 100,000 from previous studies of dystonia including focal dystonias
Location and year of publication
Rochester, USA, 1988 [3]
Tottori, Japan, 1995 [11]
SW Finland, 1996 [6]
Northern England, 1998 [5]
ESDE, 2000 [8]
generalised
focal
blepharospasm
3.4 (0.4–12.4)
–
–
1.4 (1.0–1.9)
–
29.5 (17.2–47.9)
6.1 (3.1–9.2)
–
12.9 (11.5–14.3)
11.7 (10.8–12.6)
1.7 (0.1–9.6)
1.61 (0.1–3.2)
–
3.0 (2.4–3.7)
3.6 (3.1–4.1)
cervical
8.9 (2.9–20.7)
2.9 (0.8–4.9)
20.9 (16.8–25.6)
6.1 (5.2–7.1)
5.7 (5.1–6.4)
writer’s cramp
laryngeal
6.9 (1.9–17.6)
1.6 (0.1–3.2)
–
0.7 (0.4–1.1)
1.4 (1.1–1.7)
5.2 (1.1–15.1)
–
–
0.8 (0.5–1.3)
0.7 (0.5–0.9)
Ratio includes both oromandibular and blepharospasm combined.
M et hods
The catchment area for this cross-sectional study was the city limits of Munich. Included were individuals with at least a 3-month history compatible with dystonia-plus signs of dystonia at examination,
as defined by Fahn [9], during the period of the study (January–
December 1996), and residing in the catchment area at the designated prevalence date (June 1, 1996). In Munich, services that provide
botulinum toxin treatment are concentrated in the movement disorder clinics of the two universities to which most patients are referred.
The two local neurologists and one otolaryngologist-phoniatrician
known to carry out treatment with botulinum toxin were asked to
participate in this study and provided anonymous information about
their patients with dystonia. In Germany, botulinum toxin treatment
for dystonia is covered by the health insurances (public and private
health insurances) and the social welfare in the rare case of a patient
lacking insurance coverage.
Patients who visited the dystonia and botulinum toxin clinics
during the period of the study were examined and ascertained,
whether this was their first visit or not. In addition, medical records
of patients diagnosed with any type of dystonia between 1989 and
1995 were reviewed. Patients identified by these means were contacted and interviewed in order to verify their current clinical and
demographic situation.
For each diagnosed case of dystonia, an anonymous data collection sheet was completed. Information was collected on the patients’
age and sex, as well as on the type of dystonia. Dystonia was divided
into primary dystonia with the following subgroups: dopa-responsive
dystonia, paroxysmal kinesigenic dystonia, paroxysmal dystonic
choreoathetosis and myoclonic dystonia. For secondary dystonia, the
specific cause was recorded using the following categories: tardive
dystonia (meaning exposure to neuroleptic or other dopamine receptor-blocking agents for at least 3 months and onset of dystonia within
6 months after discontinuing the drug), cerebrovascular disease, cerebral palsy, cerebral neoplasm, cerebral trauma, Wilson’s disease and
other causes. The distribution of dystonia was recorded by location.
In addition, the year of onset was also recorded to calculate the age at
onset.
All data sheets were entered on Microsoft Excel. Means and standard deviations were calculated by standard methods. Comparisons
of normally distributed continuous variables were performed using
Student’s t test. For the calculations of sex ratios, we used the one-
Service-Based Survey of Dystonia in
Munich
sample binomial test. Significance testing for differences between
proportions was calculated using the ¯2 test. All p values are twosided and at the 5% level.
For calculating the point prevalence ratio, the denominator was
the entire Munich population. We used the mean of the calculated
prevalence for December 1995 and December 1996 (1,322,883).
These values were provided by the Department of Statistics of
Munich. Confidence intervals were calculated using the Poisson distribution.
Results
A total of 230 prevalent cases were identified. Two
hundred and nine (90.9%) were seen in one of the university movement disorder clinics, 89% of them (186 cases)
were ascertained during the year 1996 as they visited one
of the university clinics and 11% (23 cases) were acquired
by review of medical records. Twenty-one patients (9.1%)
came from other clinics or practice.
One hundred and eighty-eight cases (81.7%) had primary and 42 (18.3%) secondary dystonia. No cases of
dopa-responsive, paroxysmal kinesigenic dystonia, paroxysmal dystonic choreoathetosis or myoclonic dystonia
were found.
Among the secondary dystonias, 34 cases (81.7%) were
induced by neuroleptics. Two patients had generalised
dystonia due to perinatal damage, 4 developed dystonia
after a stroke (2 of them had focal and 2 hemidystonia), 1
showed segmental brachial dystonia in a context of cortical-basal ganglionic degeneration and 1 developed focal
upper limb dystonia probably due to a local trauma.
The prevalence and sex ratios of primary dystonia subtypes are shown in table 2. Cervical dystonia was the most
common focal primary dystonia, representing more than
one half of the cases encountered, followed by blepharo-
Neuroepidemiology 2002;21:202–206
203
Downloaded by:
UB der LMU München
129.187.254.47 - 8/12/2013 12:03:49 PM
1
Type of dystonia
Table 2 . The prevalence of primary
dystonia in Munich
Type of dystonia
Blepharospasm
Cervical
Laryngeal
Other focal forms1
Segmental
Multifocal
Generalised
Number
of cases2
Prevalence3
ratio
95%
41 (21.8)
72 (38.3)
13 (6.9)
8 (4.3)
39 (20.7)
11 (5.9)
4 (2.1)
3.1
5.4
1.0
0.6
3.0
0.8
0.3
2.1–4.1
4.2–6.7
0.4–1.5
0.2–1.0
2.0–3.9
0.3–1.3
0.0–0.6
CI3
Male:female
ratio
1:2.24
1:1.34
1:1.34
1:1.04
1:2.34
1:0.84
1:1.04
1
Writer’s cramp: 3 males; oromandibular dystonia: 1 female and 1 male; pharyngeal dystonia: 1 female; focal limb dystonia: 2 females.
2
Percentages are shown in parentheses.
3
Crude prevalence ratio per 100,000.
4
Not statistically significant (¯2 and binomial test).
Table 3 . Age of onset for primary dystonia
D iscussion
Mean age of onset
SD
Blepharospasm
Cervical
Laryngeal
Segmental
Multifocal
Generalised
57.1
41.6
48.0
55.0
39.9
9.8
10.9
14.1
11.2
12.8
23.3
2.9
SD = Standard deviation.
spasm. It is also noted that laryngeal dystonia was about 5
times more prevalent than writer’s cramp. The total prevalence of dystonia was 17.4 per 100,000 [95% confidence
interval (CI) 15.1–19.7], for primary dystonia 14.2 (95%
CI 12.2–16.3), for secondary dystonia 3.2 (95% CI 2.2–
4.1) and for tardive dystonia 2.6 (95% CI 1.7–3.4). In the
group of primary dystonias, the prevalence of all focal
dystonias was 10.1 per 100,000 (95% CI 8.4–11.9), more
than 30 times that of generalised dystonia (0.3, 95% CI
0.0–0.6). Table 3 shows the mean age of onset for different types of primary dystonia. As expected, more severe
dystonias showed a younger age of onset. We observed a
significantly earlier age of onset in males as opposed to
females for blepharospasm (51.8 versus 59.6) (p = 0.04).
For the other forms of primary dystonia, there was no significant sex difference.
204
Neuroepidemiology 2002;21:202–206
To our knowledge, this study is the first to document
the prevalence of dystonia in Germany. The cases have all
been diagnosed by experts in the field of movement disorders, using internationally recognised, standardised diagnostic criteria. As part of the Epidemiological Study of
Dystonia in Europe (ESDE) Collaborative Group [7, 8],
the Munich area has the advantage of active collaboration
between the centres providing botulinum toxin treatment.
Therefore, due to these favourable referral and treatment
patterns, we could provide reliable data from patients
treated with botulinum toxin. The results presented here
may have implications regarding botulinum toxin clinic
service provision [2].
In addition, we evaluate the prevalence of secondary
dystonia. Although it is probably underreported here, the
figures may provide some idea about this generally unknown prevalence.
Our figures for primary dystonia are similar to those
from the ESDE Collaborative Group [8]. This study provides prevalence data for primary dystonia across eight
European countries (table 1).
The present study has obviously the methodological
limitations of a referral-based survey, as just the diagnosed and referred cases could be ascertained. Patients
were mostly referred for botulinum toxin treatment. This
may have led to an increased proportion of focal and segmental dystonias and at the same time to the underreporting of generalised and multifocal dystonias, since these
patients benefit less from a botulinum toxin therapy than
Castelon Konkiewitz et al.
Downloaded by:
UB der LMU München
129.187.254.47 - 8/12/2013 12:03:49 PM
Type of dystonia
Service-Based Survey of Dystonia in
Munich
cases are secondary dystonia, accounting for 7% of focal
dystonia, 35% of segmental, 38% of multifocal and 33%
of generalised dystonia.
The most common cause of secondary dystonia in the
present study was exposure to neuroleptics in 34 cases,
yielding a prevalence ratio of 2.6 per 100,000. The given
prevalence of tardive dystonia in the neuroleptic-treated
population ranges from 0.4 to 21% [16]. However, it is
likely that many of the tardive dystonia patients are not
referred to neurology clinics, as the prevalence is so high
in long-term psychiatric institutions. In agreement with
other reports [3, 5, 8, 17], the most common type of focal
dystonia was cervical dystonia, followed by blepharospasm with prevalence ratios of 5.4 and 3.1 per 100,000,
respectively. However, our estimate for writer’s cramp
differs from the series of Nutt et al. [3], Soland et al. [17],
Duffey et al. [5] and the ESDE Collaborative Group [8]
where writer’s cramp accounted for 21, 19, 6 and 12% of
focal dystonias, respectively. We found that writer’s
cramp just accounted for 2.2% of our focal dystonia
patients, yielding a prevalence of 0.2 per 100,000 (95% CI
0.0–0.5). Nevertheless, taking the CIs into account, our
figures are again comparable with those from Duffey et al.
[5] (0.7 per 100,000, 95% CI 0.4–1.1).
Comparing the mean age of onset in men and women,
we found a significantly earlier age in males for blepharospasm (51.8 versus 59.6). Sex differences depending on
the age of onset have also been recently reported in the
ESDE study [7] for primary focal and segmental dystonia.
This study observed a significantly earlier age of onset for
cervical dystonia, blepharospasm, laryngeal dystonia and
segmental dystonia in males, while for writer’s cramp and
focal limb dystonia, this trend was reversed.
In summary, as service-based study, our figures may
underestimate the true prevalence of dystonia, but due to
the characteristics of patient ascertainment, it reflects the
point prevalence of patients with dystonia seeking botulinum toxin treatment.
A ck now ledgm ent s
The authors gratefully acknowledge the statistical advice of R.
Busch. Specific acknowledgment should go to Dr. P. Franz, Dr. K.O.
Sigel and Dr. K. Joussen for providing anonymous information
about their dystonia patients.
Neuroepidemiology 2002;21:202–206
205
Downloaded by:
UB der LMU München
129.187.254.47 - 8/12/2013 12:03:49 PM
those with focal dystonia. Likewise, most patients with
generalised dystonia have childhood onset. Pediatric patients were only rarely referred to adult neurological practices for botulinum toxin which at the time of the study
was not used by neuropediatricians. These problems may
also explain why we did not ascertain any case of doparesponsive dystonia. However, the clinical presentation of
dopa-responsive dystonia is very variable and often misdiagnosed [10].
The prevalence rates of primary dystonia are lower
than those reported by Nutt et al. [3], which were based on
the records of the Mayo Clinic, Rochester, Minn., USA,
but similar to those by Duffey et al. [5], except for generalised dystonia (table 1). Duffey et al. [5] performed a community-based study in the northeast of England that
included a number of complementary methods, such as
an awareness-raising campaign, recruitment of patients
from dystonia self-help groups, as well as a postal survey
in a restricted area.
Compared with our data, Nakashima et al. [11] reported a lower prevalence of focal dystonias in the western part of Tottori Prefecture in Japan. These authors suggested that genetic factors may account for the low prevalence compared with the study of Nutt et al. [3]. In contrast, the prevalence ratio for cervical dystonia in southwestern Finland reported by Erjanti et al. [6] was more
than twice as high as the ratio observed in our study and
in Rochester.
The true prevalence of dystonia is difficult to estimate.
There are several reasons for this: as family studies have
shown [12, 13], dystonia is underreported, since many
patients with mild symptoms are not aware of their condition. Dystonia is also frequently undiagnosed. In their
series, Butler et al. [14] reported that a total of 66.7% of
patients needed at least five consultations before diagnosis was achieved and 65.7% were misdiagnosed at some
stage. Finally, as all studies looking at the prevalence of
focal dystonias are service-based rather than communitybased, except the study by Duffey et al. [5], the comparability of the centre estimates is problematic. The differences in ratios could be explained by ascertainment and
selection bias, but may also reflect an underlying environmental or genetic factor. We identified 42 patients with
secondary dystonia. We have probably missed the cases
due to metabolic or structural disorders present in childhood. Nevertheless, our proportions are strikingly similar
to those reported by Fahn et al. [15]. In their series, secondary dystonia represented 23% of all the cases: 12% of
focal dystonia, 14% of segmental, 46% of multifocal and
42% of generalised dystonia. In our series, 18.3% of the
References
206
6 Erjanti HM, Martilla RJ, Rinne UK: The prevalence and incidence of cervical dystonia in
south-western Finland. Mov Disord 1996;
11(suppl 1):215.
7 The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group: Sex-related
influences on the frequency and age of onset of
primary dystonia. Neurology 1999;10:1871–
1873.
8 The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group: A prevalence study of primary dystonia in eight European countries. J Neurol 2000;247:787–792.
9 Fahn S: Concept and classification of dystonia;
in Fahn S, Marsden CD, Calne DB (eds): Dystonia 2: Advances in Neurology. Philadelphia,
Lippincott, 1988, vol 50, pp 1–8.
10 Bandmann O, Marsden CD, Wood NW: Atypical presentations of dopa-responsive dystonia;
in Fahn S, Marsden CD, De Long MR (eds):
Dystonia 3: Advances in Neurology. Philadelphia, Lippincott-Raven, 1998, vol 78, pp 283–
290.
11 Nakashima K, Kusumi M, Inoue Y, Takahashi
K: Prevalence of focal dystonias in the western
area of Tottori Prefecture in Japan. Mov Disord 1995;10:440–443.
Neuroepidemiology 2002;21:202–206
12 Waddy HM, Fletcher NA, Harding AE, Marsden CD: A genetic study of idiopathic focal
dystonias. Ann Neurol 1991;29:320–324.
13 Fletcher NA, Harding AE, Marsden CD: A
genetic study of idiopathic torsion dystonia in
the United Kingdom. Brain 1990;113:379–
395.
14 Butler AG, Duffey POF, Hawthorne MR,
Barnes MP: The socioeconomic implications of
dystonia; in Fahn S, Marsden CD, De Long
MR (eds): Dystonia 3: Advances in Neurology.
Philadelphia, Lippincott-Raven, 1998, vol 78,
pp 349–358.
15 Fahn S, Marsden CD, Calne DB: Classification
and investigation of dystonia; in Marsden CD,
Fahn S (eds): Movement Disorders 2. London,
Butterworth, 1987, pp 332–353.
16 Adityanjee MD, Aderibigbe YA, Jampala VC,
Mathews T: The current status of tardive dystonia. Biol Psychiatry 1999;45:715–730.
17 Soland VL, Bathia KP, Marsden CD: Sex prevalence of focal dystonias. J Neurol Neurosurg
Psychiatry 1996;60:204–205.
Castelon Konkiewitz et al.
Downloaded by:
UB der LMU München
129.187.254.47 - 8/12/2013 12:03:49 PM
1 Fahn S, Bressman SB, Marsden CD: Classification of dystonia; in Fahn S, Marsden CD, DeLong MR (eds): Dystonia 3: Advances in Neurology. Philadelphia, Lippincott, 1998, vol 78,
pp 1–11.
2 Dodel RC, Kirchner A, Koehne-Volland R,
Kunig G, Ceballos-Baumann A, Naumann M,
Brashear A, Richter HP, Szucs TD, Oertel WH:
Costs of treating dystonias and hemifacial
spasms with botulinum toxin A. Pharmacoeconomics 1997;12:695–706.
3 Nutt JG, Muenter MD, Aronson A, Kurland
LT, Melton LJ: Epidemiology of focal and generalized dystonia in Rochester, Minnesota.
Mov Disord 1988;3:188–194.
4 Claypool DW, Duane DD, Ilstrup DM, Melton
LJ 3rd: Epidemiology and outcome of cervical
dystonia (spasmodic torticollis) in Rochester,
Minnesota. Mov Disord 1995;10:608–614.
5 Duffey POF, Butler AG, Hawthorne MR,
Barnes MP: The epidemiology of the primary
dystonias in the North of England; in Fahn S,
Marsden CD, De Long MR (eds): Dystonia 3:
Advances in Neurology. Philadelphia, Lippincott, 1998, vol 78, pp 121–125.